Literature DB >> 29808380

Multimodal Molecular Imaging Demonstrates Myeloperoxidase Regulation of Matrix Metalloproteinase Activity in Neuroinflammation.

Yinian Zhang1,2, Huateng Dong2,3, Daniel P Seeburg2,4, Gregory R Wojtkiewicz2, Peter Waterman2, Benjamin Pulli2, Reza Forghani2,5, Muhammad Ali2, Yoshiko Iwamoto2, Filip K Swirski2, John W Chen6.   

Abstract

Myeloperoxidase (MPO) has paradoxically been found to be able to both activate matrix metalloproteinases (MMPs) as well as inhibit MMPs. However, these regulatory effects have not yet been observed in vivo, and it is unclear which pathway is relevant in vivo. We aim to track MPO regulation of MMP activity in living animals in neuroinflammation. Mice induced with experimental autoimmune encephalomyelitis (EAE), a mouse model of neuroinflammation and multiple sclerosis, were treated with either the MPO-specific inhibitor 4-aminobenzoic acid hydrazide or saline as control. Mice underwent concurrent magnetic resonance imaging (MRI) with the MPO-specific molecular imaging agent MPO-Gd and fluorescence molecular tomography (FMT) with the MMP-targeting agent MMPsense on day 12 after induction. Biochemical and histopathological correlations were performed. Utilizing concurrent MRI and FMT imaging, we found reduced MMP activity in the brain with MPO inhibition, demonstrating MPO activity positively regulates MMP activity in vivo. In vivo MMPSense activation and MMP-9 activity correlated with MPO-Gd+ lesion volume and disease severity. This was corroborated by in vitro assays and histopathological analyses that showed MMP activity and MMP-9+ cells correlated with MPO activity and MPO+ cells. In conclusion, multimodal molecular imaging demonstrates for the first time MPO regulation of MMP activity in living animals. This approach could serve as a model to study the interactions of other biologically interesting molecules in living organisms.

Entities:  

Keywords:  Experimental autoimmune encephalomyelitis; Fluorescence molecular tomography; Magnetic resonance imaging; Matrix metalloproteinases; Myeloperoxidase; Neuroinflammation

Mesh:

Substances:

Year:  2018        PMID: 29808380      PMCID: PMC6261713          DOI: 10.1007/s12035-018-1137-2

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  30 in total

Review 1.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.

Authors:  Jialiang Hu; Philippe E Van den Steen; Qing-Xiang A Sang; Ghislain Opdenakker
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

2.  Demyelinating diseases: myeloperoxidase as an imaging biomarker and therapeutic target.

Authors:  Reza Forghani; Gregory R Wojtkiewicz; Yinian Zhang; Daniel Seeburg; Benjamin R M Bautz; Benjamin Pulli; Andrew R Milewski; Wendy L Atkinson; Yoshiko Iwamoto; Elizabeth R Zhang; Martin Etzrodt; Elisenda Rodriguez; Clinton S Robbins; Filip K Swirski; Ralph Weissleder; John W Chen
Journal:  Radiology       Date:  2012-03-21       Impact factor: 11.105

3.  Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.

Authors:  E Fainardi; M Castellazzi; T Bellini; M C Manfrinato; E Baldi; I Casetta; E Paolino; E Granieri; F Dallocchio
Journal:  Mult Scler       Date:  2006-06       Impact factor: 6.312

4.  Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier.

Authors:  Hanna Gerwien; Sven Hermann; Xueli Zhang; Eva Korpos; Jian Song; Klaus Kopka; Andreas Faust; Christian Wenning; Catharina C Gross; Lisa Honold; Nico Melzer; Ghislain Opdenakker; Heinz Wiendl; Michael Schäfers; Lydia Sorokin
Journal:  Sci Transl Med       Date:  2016-11-09       Impact factor: 17.956

Review 5.  Hypochlorous acid and taurine-N-monochloramine in periodontal diseases.

Authors:  A Mainnemare; B Mégarbane; A Soueidan; A Daniel; I L C Chapple
Journal:  J Dent Res       Date:  2004-11       Impact factor: 6.116

6.  Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor.

Authors:  J M Clements; J A Cossins; G M Wells; D J Corkill; K Helfrich; L M Wood; R Pigott; G Stabler; G A Ward; A J Gearing; K M Miller
Journal:  J Neuroimmunol       Date:  1997-04       Impact factor: 3.478

7.  Activatable magnetic resonance imaging agents for myeloperoxidase sensing: mechanism of activation, stability, and toxicity.

Authors:  Elisenda Rodríguez; Mark Nilges; Ralph Weissleder; John W Chen
Journal:  J Am Chem Soc       Date:  2010-01-13       Impact factor: 15.419

8.  Bone marrow-derived cells are the major source of MMP-9 contributing to blood-brain barrier dysfunction and infarct formation after ischemic stroke in mice.

Authors:  Guangming Wang; Qingmin Guo; Mohammed Hossain; Vince Fazio; Emil Zeynalov; Damir Janigro; Marc R Mayberg; Shobu Namura
Journal:  Brain Res       Date:  2009-07-29       Impact factor: 3.252

9.  Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase.

Authors:  Michael O Breckwoldt; John W Chen; Lars Stangenberg; Elena Aikawa; Elisenda Rodriguez; Shumei Qiu; Michael A Moskowitz; Ralph Weissleder
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-14       Impact factor: 11.205

10.  Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis.

Authors:  Elizabeth Gray; Taya L Thomas; Samar Betmouni; Neil Scolding; Seth Love
Journal:  Brain Pathol       Date:  2007-11-27       Impact factor: 6.508

View more
  5 in total

1.  Myeloperoxidase Molecular MRI Reveals Synergistic Combination Therapy in Murine Experimental Autoimmune Neuroinflammation.

Authors:  Anning Li; Yue Wu; Benjamin Pulli; Gregory R Wojtkiewicz; Yoshiko Iwamoto; Cuihua Wang; Jing-Hui Li; Muhammad Ali; Xiaoyuan Feng; Zhenwei Yao; John W Chen
Journal:  Radiology       Date:  2019-09-03       Impact factor: 11.105

Review 2.  Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment.

Authors:  Aline M Thomas; Frederik Barkhof; Jeff W M Bulte
Journal:  Radiology       Date:  2022-04-26       Impact factor: 29.146

3.  Potential Therapeutic Features of Human Amniotic Mesenchymal Stem Cells in Multiple Sclerosis: Immunomodulation, Inflammation Suppression, Angiogenesis Promotion, Oxidative Stress Inhibition, Neurogenesis Induction, MMPs Regulation, and Remyelination Stimulation.

Authors:  Mohsen Abbasi-Kangevari; Seyyed-Hadi Ghamari; Fahimeh Safaeinejad; Soheyl Bahrami; Hassan Niknejad
Journal:  Front Immunol       Date:  2019-02-20       Impact factor: 7.561

Review 4.  Heavy Metal-Induced Cerebral Small Vessel Disease: Insights into Molecular Mechanisms and Possible Reversal Strategies.

Authors:  Jayant Patwa; Swaran Jeet Singh Flora
Journal:  Int J Mol Sci       Date:  2020-05-29       Impact factor: 5.923

Review 5.  The Role of Inflammation and Myeloperoxidase-Related Oxidative Stress in the Pathogenesis of Genetically Triggered Thoracic Aortic Aneurysms.

Authors:  Cassandra Malecki; Brett D Hambly; Richmond W Jeremy; Elizabeth N Robertson
Journal:  Int J Mol Sci       Date:  2020-10-16       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.